WO2005026348A1 - スクリーニング方法 - Google Patents
スクリーニング方法 Download PDFInfo
- Publication number
- WO2005026348A1 WO2005026348A1 PCT/JP2004/013396 JP2004013396W WO2005026348A1 WO 2005026348 A1 WO2005026348 A1 WO 2005026348A1 JP 2004013396 W JP2004013396 W JP 2004013396W WO 2005026348 A1 WO2005026348 A1 WO 2005026348A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell line
- expression
- antibody
- cells
- cell
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56927—Chlamydia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Definitions
- the present invention relates to a remedy for arteriosclerosis and a method and kit for screening for a preventive and remedy for its complications. More specifically, the present invention relates to a 60 kDa heat shock protein (hereinafter, referred to as “HSP60”) derived from Chlamydia pneumoniae (hereinafter sometimes abbreviated as “Cp”). And a screening method for a therapeutic drug for arteriosclerosis and a prophylactic / therapeutic drug for its complications using a mammalian monocyte cell line, and a kit therefor.
- HSP60 60 kDa heat shock protein derived from Chlamydia pneumoniae
- Chlamydia pneumoniae an obligate intracellular parasitic gram-negative bacterium, is one of the major causative agents of central pneumonia, as well as arteriosclerosis, asthma, chronic obstructive pulmonary disease, Alzheimer's disease, A link to chronic disease has been suggested.
- Arteriosclerosis (especially atherosclerosis) is the leading cause of death in Japan, the United States and Europe in acute coronary syndrome (ACS; including acute myocardial infarction and unstable angina) and cerebrovascular disease (especially ischemic cerebrovascular disease). Cerebral infarction, cerebral embolism, cerebral thrombosis, etc.).
- ACS acute coronary syndrome
- cerebrovascular disease especially ischemic cerebrovascular disease. Cerebral infarction, cerebral embolism, cerebral thrombosis, etc.).
- the association of Cp with arteriosclerosis has begun to be noticed since a study of road fatalities reported that atherosclerotic lesions correlated with the prevalence of serum anti-Cp antibodies (Saikku, P Et al., Lancet (UK), 1988, Volume 2, pp. 983-9886).
- C p derived HSP 6 0 (hereinafter, "sometimes referred to as the chs P 60 j) Gahi detected from the capital of atherosclerotic lesions (Kol, A. et al., Circulation (USA), 1 9 9 8 year, 9 8 Certificates, pp.
- Ma tri Kkusumeta primary macro port phage differentiated from human monocytes is one of collagenolytic enzymes when stimulated with chs P 60 It has been reported that the production of oral proteinase-9 (hereinafter sometimes abbreviated as “Maraudal P-9”) is increased (Vehmaan-Kreula, P. et al., Arterioscler. Thromb. Vase. Biol. (USA), 2001, Vol. 21, pp. El — e 8).
- MMP-9 is overproduced in advanced human atherosclerotic lesions, and is strongly expressed and activated especially in ruptured lesions (Loftus, ⁇ ⁇ et al., Stroke (USA), 2000, No. 3). 1 roll, pp. 40-47).
- high levels of MMP-9 in plasma may be a risk factor for death from cardiovascular disease, and polymorphisms in the MMP-9 gene are stable.
- Significantly correlated with future incidence of cardiovascular events in angina patients. (Blankenberg, S. et al., Circulation (USA), 2003, Volume 107, Volume 157. 9-15885)
- MMP-9 knockout mice the progression of lesions in atherosclerosis is suppressed, etc. (Luttun, A. et al., Circulation ( United States), 2004, Vol. 109, pp. 148-141).
- Atherosclerosis refers to a condition in which the vascular lumen is narrowed by plaques covered with collagen fibers, but clinical findings suggest that ACS such as myocardial infarction and angina pectoris may occur. It is considered that plaque characteristics rather than stenosis are more important in the event of coronary artery with thrombus formation leading to stenosis. In other words, the hypothesis that lesions with a large lipid core and a thin fibrous cap covering them are susceptible to breakage and have a high risk of developing complications is supported (Libby, P., Circulation ( (United States), 1995, Vol. 91, pp. 284-4—2805).
- Collagen is the main component of the fibrous cap covering the plaque surface, and matrix meta-oral proteases (MMPs), which are collagenases, can directly weaken the cap (Young, JL et al., Thrombosis and Haemostasis (Germany), 2008, Vol. 88, pp. 554-567, Jones, CB) et al., Cardiovascular Research (Netherlands), 2003, Vol. 59, pp. 8 1 2 — 8 2 3). Plaque rupture is caused by the fact that Mac phage ⁇ vascular smooth muscle cells activated by T cells take up oxidized LDL 'and foam, and the fibrous cap is weakened by MMPs secreted from the resulting foam cells. And it is thought to happen. Among them, MMP-9 is considered to play a major role in plaque destabilization, since significant production enhancement was observed in broken plaque.
- MMPs matrix meta-oral proteases
- lasidipine a hypertension treatment, suppressed ⁇ -9 secretory production in mouse macrophages stimulated by phorbol ester and tumor necrosis factor (TNF- ⁇ ), but (Be ⁇ losta, S. et al. The Journal of Pharmacology and Experiments ⁇ Therapeutics (USA), 2001, Vol. 296, No. 3, pp. 7 36— '7 4 3), Results of clinical trials show that lasidipine inhibits the progression of arteriosclerosis The power to be effective has been demonstrated (Zanchetti, A. et al., Circulation (USA), 2010, Vol.
- substances that can suppress the overproduction of ⁇ P-9 from macula phage or the like due to CP infection or chsp60 stimulation can be used for treatment of arteriosclerosis, suppression of progression (especially ACS, ischemic cerebrovascular It is expected as a new drug that is effective for the prevention of serious complications such as disorders) or the treatment of those complications.
- a compound screening system having sufficient sensitivity to be used as an evaluation system for such a drug and having excellent reproducibility has not been known so far. It is possible to induce high levels of ⁇ -9 production by stimulating with cholesterol esters or TNF- ⁇ , as in the efficacy evaluation system for statins and lacidipine described above.
- an object of the present invention is to provide a screening method capable of selecting a substance capable of suppressing the overproduction of MMP-9 from Mac phage or the like caused by C ⁇ infection or chsp60 stimulation with high sensitivity, reproducibility and efficiency.
- the present inventors have conducted intensive studies to achieve the above object, and as a result, using a monocyte cell line (eg, THP-1 cell line) as an MMP-9-producing cell, infected it with CP.
- a monocyte cell line eg, THP-1 cell line
- MMP-9 expression was significantly higher than monocytes isolated from blood or primary macula phages that differentiated them.
- the present inventors have further studied based on these findings, and have completed the present invention.
- a monocyte cell line and a 60 kDa heat shock protein derived from Chlamydia 'pneumoniae or a partial peptide thereof or a salt thereof or a cell capable of producing the same (the cell is a monocyte cell line)
- a method for treating atherosclerosis and preventing or preventing Z or its complications, screening for therapeutic substances
- a monocyte cell line is selected from the group consisting of THP_1, U-937, P31 / FUJ, RAW 267.4 and J774A.
- the monocyte cell line is a THP-1 cell line.
- a monocytic cell line and a cell capable of producing a 60 kDa heat shock protein derived from 'Chlamydia' pneumoniae or its partial peptide or a salt thereof, or a cell capable of producing it which may be the same as or different from keratinocytes), for treating arteriosclerosis and / or for preventing its complications.
- Chlamydia pneumoniae-derived 6 O kDa heat shock protein or a cell capable of producing a partial peptide or a salt thereof is a Chlamydia pneumoniae.
- a monocyte cell line is selected from the group consisting of THP-1, U-937, P31FUJ, RAW264.7 and J774A.1.
- Atherosclerosis comprising a substance capable of inhibiting the induction of Matrix meta-oral proteinase 9 gene expression in mammalian cells by a 60 kDa heat shock protein derived from Chlamydia pneumoniae Treatment and / or prevention of its complications
- FIG. 1 shows the changes in the induction of TNFa (FIG. 1A) and MMP-9 (FIG. 1B) production in monocyte cell lines induced by chsp60 stimulation.
- FIG. 2 shows the dependence of the induction of MMP-9 production in a monocyte cell line on the concentration of chsp60. Detailed description of the invention
- the method for treating arteriosclerosis and the prevention of Z or its complications of the present invention is as follows: a monocyte cell line and a 60 kDa heat shock protein derived from Chlamydia pneumoniae. Alternatively, a partial peptide thereof, a salt thereof, or a cell capable of producing the same is used.
- treatment of arteriosclerosis means, for example, suppression of progression of atherosclerotic lesions ⁇ stabilization of plaque
- “complications of arteriosclerosis” include, for example, acute myocardial infarction, Cardiovascular and cerebral vascular events such as acute coronary syndrome (ACS) such as unstable angina, cerebral infarction, cerebral thrombosis, and cerebral embolism.
- ACS acute coronary syndrome
- the chsp60 used in the present invention is not particularly limited in its origin as long as it is a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 2, for example, naturally It can be isolated from various isolates of Chlamydia pneumoniae (eg, clinical isolates from pneumonia patients). Further, it may be chemically synthesized based on the amino acid sequence represented by SEQ ID NO: 2, and may be obtained from a transformant into which a nucleic acid having a base sequence encoding the amino acid sequence has been introduced. It may be a produced recombinant protein. Alternatively, the nucleic acid is It may be a protein synthesized biochemically using a cell-free (transcription) translation system.
- the amino acid sequence J substantially identical to the amino acid sequence represented by SEQ ID NO: 2 is at least about 60%, preferably at least about 70%, more than the amino acid sequence represented by SEQ ID NO: 2.
- the amino acid sequence has about 80% or more, particularly preferably about 90% or more, and most preferably 95% or more of homology.
- homology refers to an optimal alignment (preferably, the algorithm is optimized for optimal alignment) when two amino acid sequences are aligned using a mathematical algorithm known in the art.
- the ratio of the same amino acid and similar amino acid residues to all overlapping amino acid residues (° / 0 ) can be taken into account.
- Similar amino acids means amino acids that are similar in physicochemical properties, such as aromatic amino acids (Phe, Trp, Tyr), aliphatic amino acids (Ala, Leu, Ile, Val), and polar amino acids (Gln, Asn), basic amino acids (Lys, Arg, His), acidic amino acids (Glu, Asp), amino acids with hydroxyl groups (Ser, Thr), small side chain amino acids (Gly, Ala, Ser, Thr, Met), etc. Amino acids classified into the same group as above. It is expected that such substitution with a similar amino acid will not change the phenotype of the protein (ie, a conservative amino acid substitution). Examples of conservative amino acid substitutions are well known in the art and are described in various documents (see, for example, Bowie et al., Science, 247: 1306-1310 (1990)).
- Algorithms for determining the homology of amino acid sequences include, for example, the algorithm described in Karlin et al., Pro Natl. Acad. Sci. USA, 90: 5873-5877 (1993) [The algorithm is NBLAST and XBLAST program (version 2.0) This thread is inserted (Altschul et al., Nucleic Acids Res., 25 .: 3389-3402 (1997))], Needle sleep et al., J. Mol. Biol.
- the amino acid sequence that is substantially identical to the amino acid sequence represented by SEQ ID NO: 2 is at least about 60%, preferably about 60%, of the amino acid sequence represented by SEQ ID NO: 2.
- the “protein containing an amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 2” includes the aforementioned “amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 2”. And a protein having substantially the same activity as the protein containing the amino acid sequence represented by SEQ ID NO: 2.
- “activity” refers to mammals (eg, humans, monkeys, lions, pomas, pigs, higgs, goats, dogs, cats, puppies, nomsters, monoremots, mice, rats, etc.).
- MMP-9 expression enhancing activity in cells eg, leukocyte cells including monocyte cells such as monocytes and macrophages, and cells existing in blood or vascular wall such as vascular smooth muscle cells
- plaque destabilization fibrosis "Substantially homogeneous” means that their activities are qualitatively equivalent (eg, physiologically or pharmacologically). Therefore, It is preferable that the expression of MMP-9 is as high as the strong activity (eg, 0.5 to 2 times). The quantitative factors such as the force S, the degree of these activities, and the molecular weight of the protein may be different.
- MMP-9 expression-enhancing activity can be measured, for example, by the method described in Non-Patent Document 5 or the like (ELISA using anti-banded P-9 antibody, gelatin zymography, quantitative RT-PCR) or a method similar thereto. Can be performed according to
- ch S p60 for use in the present invention, for example, 1) one or two or more of the amino acid sequence represented by SEQ ID NO: 2 (e.g. 1 to 5 0 or so, 3 0 preferably 1 to Amino acid sequence in which about 1 to 10 amino acids have been deleted, and more preferably about 1 to 10 amino acids, and more preferably 1 to 5 amino acids.
- SEQ ID NO: 2 e.g. 1 to 5 0 or so, 3 0 preferably 1 to Amino acid sequence in which about 1 to 10 amino acids have been deleted, and more preferably about 1 to 10 amino acids, and more preferably 1 to 5 amino acids.
- the position of the insertion, deletion or substitution is not particularly limited.
- the chsp60 in the present invention preferably has an amino acid sequence represented by SEQ ID NO: 2, and has a chlamydia 'pneumoniae KKpn- ;! strain [Ki shimoto T. and Soejima R., Intern. Med., 32: 934- 937 (1993)] [the KKpn-1 Chs P 60 recombinant E.
- proteins and peptides are described according to the convention of peptide labeling, with the N-terminus (amino terminus) at the left end and the C-terminus (carboxyl terminus) at the right end. Containing the amino acid sequence represented by SEQ ID NO: 2.
- R in the ester e.g., methyl, Echiru, n - propyl, isopropyl
- alkyl groups such as n- butyl; for example, C 3 _ 8 Shikuroarukinore groups such as cyclohexyl consequent opening pentyl, consequent opening; e.g. , phenyl, alpha - 12 Ariru group - C 6, such as naphthyl; - 14 Ararukiru group C 7 such as ⁇ - naphthylmethyl etc.
- a- Nafuchiru CM alkyl group for example, benzyl, phenylene Lou alkyl group, such as full Enechiru
- a piperyloxymethyl group is used.
- chsp60 has a carboxyl group (or carboxylate) other than the C-terminus
- those in which the carboxyl group is amidated or esterified are also included in chsp60.
- the ester in this case, for example, the above-mentioned C-terminal ester and the like are used.
- chsp60 has an amino group at the N-terminal amino acid residue (eg, a methionine residue) protected with a protecting group (eg, an acyl group such as an alkanol such as a formyl group or an acetyl group), Cut in vivo N-terminal daltamine residue generated by cleavage is pyroglutamine-oxidized.
- a protecting group eg, an acyl group such as an alkanol such as a formyl group or an acetyl group
- Cut in vivo N-terminal daltamine residue generated by cleavage is pyroglutamine-oxidized.
- Substituents on the side chains of amino acids in the molecule for example, --OH, --SH, amino group, imidazole group, indole group Or a guadino group
- an appropriate protecting group for example, an acyl group such as an alkanol group such as a formyl group or an
- chs P 60 partial peptide (hereinafter, sometimes simply referred to as "partial peptide of the present invention") is a pair flops tide having a partial amino acid sequence of chsp60 described above, and chsp60 substantially the same activity Any one may be used as long as it has.
- “substantially the same activity” is as defined above.
- the measurement of "substantially equivalent activity” can be Nau row as in the case of chs P 60.
- the partial peptide of the present invention includes, for example, those having a partial amino acid sequence including a region involved in enhancing MMP-9 expression in mammalian cells, among the amino acid sequence represented by SEQ ID NO: 2, and the like. Used.
- a peptide having at least 50 or more, preferably 100 or more, more preferably 200 or more amino acids is preferable.
- the partial peptide of the present invention may have a carboxyl group (one COOH), a carboxylate (—COO—), an amide (one C ⁇ NH 2 ) or an ester (one COOR) at the C-terminus.
- R in the ester those similar to those described above for chspSO can be mentioned.
- the partial peptide of the present invention has a carboxyl group (or a carboxylate) other than the C-terminus, those in which the carboxyl group is amidated or esterified are also included in the partial peptide of the present invention.
- the ester in this case, for example, those similar to the C-terminal ester and the like are used.
- the partial peptide of the present invention includes a peptide in which the amino group of the N-terminal amino acid residue is protected with a protecting group, and a peptide in which the N-terminal daltamine residue is oxidized with glutamine.
- examples include those in which the substituent on the side chain of the amino acid in the molecule is protected with an appropriate protecting group, and those in which sugar chains are bonded, such as so-called glycopeptides.
- the chs P 60 or a salt thereof partially peptidyl 'de physiologically acceptable acids (eg, inorganic acids, organic acids) or bases (eg, alkali metal salts) and salts with such used, preparative Ri
- physiologically acceptable acid addition salts are preferred.
- Such salts include, for example, salts with inorganic acids (eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid) or organic acids (eg, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, Salts with succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid) are used.
- inorganic acids eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid
- organic acids eg, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid
- chs P 60 or a salt thereof can be prepared as described above, the protein separation and purification techniques per se publicly known from cells of the various C p strains.
- a culture medium suitable for chlamydia growth by infecting Cp with suitable host cells such as human lung-derived cultured cells (eg, HL cells) (eg, Eagle medium supplemented with cycloheximide) After culturing for an appropriate period of time, disrupt cells by sonication or the like, and purify large quantities of Cp cells by density gradient centrifugation.
- the soluble fraction is separated by reverse phase chromatography, ion exchange chromatography, affinity chromatography, or the like, thereby obtaining chsp60 or a salt thereof. Can be purified.
- chsp60 or a partial peptide thereof or a salt thereof can also be produced according to a known peptide synthesis method.
- the peptide synthesis method may be, for example, any of a solid phase synthesis method and a liquid phase synthesis method.
- the target protein can be produced by condensing a partial peptide or amino acid capable of constituting chsp60s with the remaining portion and, when the product has a protecting group, removing the protecting group.
- condensation and the elimination of the protecting group are performed according to a method known per se, for example, the methods described in the following 1) to 5).
- the protein (peptide) thus obtained can be purified and isolated by a known purification method.
- the purification method include solvent extraction, distillation, column chromatography, liquid chromatography, recrystallization, and combinations thereof.
- the free form can be converted into an appropriate salt by a known method or a method analogous thereto, and conversely, the protein (peptide) '
- the salt can be converted to a free form or another salt by a known method or a method analogous thereto.
- ch the synthesis of SP 60 include, typically, may be a commercially available resin for protein synthesis.
- resins include, for example, chloromethyl resin, hydroxymethyl resin, benzhydrylamine resin, aminomethyl resin, Benzoxybenzyl alcohol resin, 4-methylinobenzhydrylamine resin, PAM resin, 4-hydroxymethylmethylphenylacetamide methyl resin, polyacrylamide resin, 4- (2,, 4, Examples thereof include 1-dimethyoxyphenyl-2-hydroxymethyl) phenoxy resin, and 41- (2,4, -dimethoxy-Fmocaminoethyl) phenoxy resin.
- an amino acid having an ⁇ -amino group and a side chain functional group appropriately protected is condensed on the resin according to the sequence of the target protein (peptide) according to various known condensation methods.
- proteins and other substances are cleaved from the resin, and at the same time, various protecting groups are removed.
- a disulfide bond formation reaction in a molecule is carried out in a highly diluted solution to obtain the target protein (peptide) or its amide Get the body.
- carbodiimides are particularly preferable.
- the carbodiimides DCC, ⁇ , N'-diisopropyl rubodiimid, ⁇ -ethyl- ⁇ , 1- (3-dimethylaminopropyl) carbodiimide and the like are used.
- Condensation of the protected amino acid can be performed, for example, by directly adding the protected amino acid to the resin together with an activating reagent and a racemization inhibitor (e.g., HOBt, HOOBt), or by adding the protected amino acid in advance to a symmetric anhydride or HOB ester or Activated as HOOB t-ester and then added to the resin.
- an activating reagent e.g., HOBt, HOOBt
- the solvent used for activating the protected amino acid or condensing with the resin is appropriately selected from solvents known to be usable for the protein condensation reaction.
- acid amides such as N, N-dimethylformamide, N, N-dimethylacetamide, N-methylpyrrolidone; methylene chloride; Halogenated hydrocarbons such as trifluoroethanol; sulfoxides such as dimethyl sulfoxide; amines such as pyridine; ethers such as dioxane and tetrahydrofuran; and ethers such as acetonitrinole and propionitrile. Tolyls; esters such as methyl acetate and ethyl acetate; or appropriate mixtures thereof.
- the reaction temperature is appropriately selected from the range known to be used for the protein condensation reaction, and is usually selected from the range of about 120 ° C to 50 ° C.
- the activated amino acid derivative is usually used in a 1.5 to 4-fold excess. If condensation is insufficient as a result of the test using the dihydrin reaction, sufficient condensation can be achieved by repeating the condensation reaction without removing the protecting group.
- condensation is not sufficient even after repeating the condensation reaction, sufficient condensation can be carried out by acetylating the unreacted amino acid with acetic anhydride or acetylimidazole.
- the method for protecting the functional groups that should not be involved in the reaction of the raw materials, the method for elimination of the protective groups and the protective groups, and the method for activating the functional groups involved in the reaction are appropriately selected from known groups or known means Can.
- Examples of the protecting group for the amino group of the starting amino acid include Z, Boc, t-Pentinoleoxycanoleponinole, isobonoleninoleoxy power / reponinole, 4-methoxybenzyloxycarbonyl, and C-methoxybenzyloxycarbonyl.
- 1 Z, Br — Z, adamantyl oxycanoleboninole, tri-funoleoloacetinole, phta leonore, honoleminole, 2 —Nitropheninolenes renoenore, dihue-norephosfuinothioinole, F m 0 c and the like.
- the carboxyl group of the starting amino acid is, for example, alkyl esterified (for example, straight chain such as methinole, ethinole, propinole, petitinole, t-butylinole, cyclopentinole, cyclohexinole, cycloheptyl, cyclooctinole, 2-rydamantyl, etc.) , Branched or cyclic alkyl esterification), aral Kill esterification (eg, Nginoleestenole, 412 Trobenginoleestenole, 4-Methoxypentinoleestenole, 4-chlorobenzineoleestenole, Benzhydryl esterification), phenacyl esterification, penzinoleoxy It can be protected by carboxylhydrazide, t-butoxycarbhydrazide, tritylhydrazide and the like.
- alkyl esterified for example, straight chain such
- the hydroxyl group of serine can be protected, for example, by esterification or etherification.
- Suitable groups for esterification include, for example, those derived from carbonic acids such as lower (C ⁇ ) alkanol groups such as acetyl groups, aroyl groups such as benzoyl groups, benzyloxycarbonyl groups and ethoxycarbonyl groups. Groups and the like.
- Examples of the group suitable for etherification include a benzyl group, a tetrahydroviranyl group, and a t-butyl group.
- protecting groups for histidine imidazonoles include Tos, 4-methoxy-1,2,3,6-trimethinolebenzenesnolehoninole, DNP, benzyloxymethyl, Bum, Boc, and Trt. , Fmoc and the like are used.
- Methods for removing (eliminating) protecting groups include, for example, catalytic reduction in a hydrogen stream in the presence of a catalyst such as Pd-black or Pd-carbon; anhydrous hydrogen fluoride, methanesnolefonic acid, and triflic acid.
- Acid treatment with dichloromethane, trifluoroacetic acid, or a mixture thereof; base treatment with diisopropylethylamine, triethylamine, piperidine, piperazine, etc .; reduction with sodium in liquid ammonia. .
- the elimination reaction by the above acid treatment is generally performed at a temperature of about 120 ° C to 40 ° C.
- cation scavengers such as' anisole, phenol, thioaesole, methacresolone, noracrezo monoleme, dimethinoresnoleide, 1,4-butanedithiol, 1,2-ethanedithiol, etc.
- the addition is effective.
- the 2,4-di-trophenyl group used as an imidazole protecting group for histidine is removed by thiophenol treatment.
- the forminole group used as an indole protecting group for tributofan includes deprotection by acid treatment in the presence of 1,2-ethanedithionole, 1,4-butanedithionole, etc., as well as dilute sodium hydroxide solution, It is also removed by alkaline treatment with dilute ammonia.
- Activated carboxyl groups of the starting amino acids include, for example, the corresponding acid anhydrides, azides, active esters [alcohols (eg, pentachlorophenol, 2, 4, 5 Phenols, 2,4-dinitrophenol, cyanomethanol alcohol, paranitrophenol, HONB, N-hydroxysuccinimide, N-hydroxyphthalimid, and esters with HOBt).
- active esters eg, pentachlorophenol, 2, 4, 5 Phenols, 2,4-dinitrophenol, cyanomethanol alcohol, paranitrophenol, HONB, N-hydroxysuccinimide, N-hydroxyphthalimid,
- an amide form of a protein for example, after amidating and protecting a monocarboxyl group of the carboxy terminal amino acid, a peptide chain is added to the amino group side to a desired chain length. After the elongation, a protein (peptide) in which only the N-terminal ⁇ -amino group protecting group of the peptide chain has been removed and a protein (peptide) in which only the C-terminal carboxyl group protecting group has been removed are produced, The two proteins (peptides) are condensed in a mixed solvent as described above. Details of the condensation reaction are the same as described above.
- the ester form of the protein (peptide) can be obtained, for example, by condensing the carboxyl group of the carboxy terminal amino acid with a desired alcohol to form an amino acid ester, and then treating the ester form of the protein (peptide) as described above. Can be obtained.
- the partial peptide or a salt thereof of the present invention can also be produced by cleaving chsp60 or a salt thereof with an appropriate peptidase.
- Chsp60 such is prepared by culturing the Chsp60 or transformant transformed with a expression vector containing a nuclear 'acid encoding a partial peptide thereof, separating and purifying ch S p60 acids from the resulting culture Yobutsu You can also.
- the nucleic acid encoding chsp60 or a partial peptide thereof may be DNA or RNA, or may be a DNAZRNA chimera.
- DNA is used.
- the nucleic acid may be double-stranded or single-stranded. In the case of double-stranded DNA, double-stranded DNA or double-stranded RNA or DNA: RNA hybrid can be used. In the case of a single strand, it may be a sense strand (ie, a coding strand) or an antisense strand (ie, a non-coding strand).
- the DNA encoding chsp60 or its partial peptide was prepared by reverse transcription from genomic DNA extracted from Cp cells by conventional methods, or RNA extracted from Cp cells by conventional methods (or by RT-PCR). Amplified DNA) and chemically synthesized DNA.
- DNA encoding chsp60 or a partial peptide thereof specifically, a DNA containing the nucleotide sequence represented by SEQ ID NO: 1 or the nucleotide sequence represented by SEQ ID NO: 1 under highly stringent conditions Hybridi A protein (eg, an MMP-9 expression-enhancing activity) having substantially the same activity as the protein containing the amino acid sequence represented by SEQ ID NO: 2 ), And the like.
- Examples of a DNA that can hybridize with the base sequence represented by SEQ ID NO: 1 under high stringent conditions include, for example, about 60% in a region overlapping with the base sequence represented by SEQ ID NO: 1.
- DNA having a nucleotide sequence having a homology of about 70% or more, more preferably about 80% or more, particularly preferably about 90% or more, and most preferably about 95% or more is used.
- Hybridization is carried out by a method known per se or a method analogous thereto, for example, Molecular Cloning, 2nd edition, U. Sambrook et al., Cold Spring Harbor Lab. Press, 1989. ) [This can be done according to the method described on my own. When a commercially available library is used, hybridization can be performed according to the method described in the attached instruction manual. Hybridization can be performed, preferably according to high stringency conditions.
- stringent conditions refers to about 60% or more, preferably about 70% or more, more preferably about 80% in a region overlapping with the base sequence represented by SEQ ID NO: 1. Or more, particularly preferably about 90% or more, and most preferably about 95% or more under conditions capable of hybridizing with a DNA having a nucleotide sequence having a homology of about 95% or more.
- a sodium concentration of about 19 to 40 m M, preferably about 19 to 20 mM at a temperature of about 50 to 70 ° C, preferably about 60 to 65 ° C, particularly preferably at a sodium concentration of about 19 mM. Is about 65 ° C.
- the salt concentration of the hybridization solution the temperature of the hybridization reaction, the probe concentration, the length of the probe, the number of mismatches, and the hybridization.
- the desired stringency can be easily adjusted by appropriately changing the reaction time, salt concentration of the washing solution, washing temperature and the like.
- the DNA encoding chsp60 or its partial peptide is preferably a DNA containing a part of the nucleotide sequence represented by SEQ ID NO: 1 or a part of the nucleotide sequence in which the reading frame of the codon matches (that is, in-frame). And so on.
- chs P 60 or a DNA co one de that part peptide is or The protein using synthetic DNA primers one having a portion of the base sequence that co one de the peptide, cells producing chs P 60 (e.g. Ability to amplify by PCR using genomic DNA or cDNA derived from Cp cells) as a mold, or an appropriate cloning vector for the genomic DNA fragment or cDNA (eg, Batateriophage, Plasmid, Cosmid) Phagemid), and screened by coloie or plaque hybridization using a probe labeled with a DNA fragment coding for a part or all of chsp60 or synthetic DNA as a probe.
- synthetic DNA primers one having a portion of the base sequence that co one de the peptide
- cells producing chs P 60 e.g. Ability to amplify by PCR using genomic DNA or cDNA derived from Cp cells
- an appropriate cloning vector for the genomic DNA fragment or cDNA eg, Batateriophag
- hybridization can be carried out, for example, according to the method described in Molecular Cloning, 2nd edition (described above). When a commercially available library is used, hybridization can be performed according to the method described in the instruction manual attached to the library.
- a DNA encoding chsp60 or a partial peptide thereof can also be cloned by an antibody screening method using an anti-chsp60 antibody.
- the RACE method can be used as a method for quickly and easily obtaining a full-length cDNA clone.
- oligonucleotides homologous to the partial base sequences of the sense strand and antisense strand of double-stranded DNA corresponding to a part of the cDNA of chsp60 are synthesized, and appropriate oligonucleotides are used.
- a DNA encoding chsp60 or a partial peptide thereof can be chemically synthesized based on the nucleotide sequence represented by SEQ ID NO: 1 using a commercially available automatic DNA / RNA synthesizer. It is also possible to synthesize a full-length DNA by synthesizing fragments of the sense strand and the antisense chain so as to overlap each other, hybridizing these fragments, and combining the PCR method and the like.
- the DNA base sequence can be determined using known kits such as Mutan " 1 -super Express Km (Takara Shuzo Co., Ltd.), Mutan TM -K (Takara Shuzo Co., Ltd.), 0M-LA PCR, and Gapped duplex.
- the conversion can be carried out according to a method known per se such as the Kunkel method or a method similar thereto.
- the DNA encoding the cloned protein can be used as it is, after digestion with a restriction enzyme, or after addition of a linker, if desired.
- the DNA may have ATG as a translation initiation codon at the 5 'end and TAA, TGA or TAG as a translation termination codon at the 3' end. These translation start codon and translation stop codon can be added using a suitable synthetic DNA adapter. '
- chs P 60 or expression downy click terpolymer containing a nucleic acid co one de that part peptide may, for example, excising the desired DNA fragment from the DNA encoding Chsp60, the DN A fragment suitable expression vector in It can be produced by connecting to the downstream of the promoter.
- Escherichia coli-derived plasmids eg, pBR322, pBR325, pUCl2pUCl3; a plasmid derived from Bacillus subtilis (eg, pUB110, pTP5, pC194); a plasmid derived from yeast (eg, p SH19, pSH15); pacteriophages such as ⁇ phage; animal viruses such as retroinoles, vacsuawinores, and noculoinoles; pA1-11, pXT1, Rc / CMV; pRc / RSV, pcDNAI / Neo, etc. are used.
- Any promoter can be used as long as it is appropriate for the host used for gene expression.
- T 7 promoter When the host is a Eshieri HERE spp, t rp promoter, lac flop port motor, rec A promoter, LP L promoter, lpp promoter one coater, Le Shi like are preferred T 7 promoter.
- a PH05 promoter When the host is yeast, a PH05 promoter, a PGK promoter, a GAP promoter, an ADH promoter and the like are preferred.
- a polyhedrin promoter When the host is an insect cell, a polyhedrin promoter, a P10 promoter and the like are preferable.
- SRo when the host is an animal cell, SRo; promoter, SV40 promoter, LTR promoter, CMV (cytomegalovirus) promoter, HSV-TK promoter and the like are used. Among them, preferred are CMV promoter, SRa promoter and the like.
- Examples of the expression vector include, in addition to the above, an enhancer, a splicing signal, a polyA addition signal, a selection marker, an SV40 replication origin (hereinafter sometimes abbreviated as SV40 ori), if desired. What they contain can be used.
- a selection marker for example, Ann Pishiri down resistance gene (hereinafter sometimes abbreviated as Am p r), Neomai Shin-resistant gene (hereinafter sometimes abbreviated as o r, G 4 1 8 resistance), Te Torasaitarin resistance gene, hygromycin resistance gene, dihydric de port reductase (hereinafter sometimes abbreviated as dhfr) gene [Meso-trexate (MTX) resistance].
- Am p r Ann Pishiri down resistance gene
- Neomai Shin-resistant gene hereinafter sometimes abbreviated as o r, G 4 1 8 resistance
- Te Torasaitarin resistance gene hereinafter sometimes abbreviated as hygromycin
- a signal sequence suitable for the host may be added to the N-terminal side of chsp60. If the host is Escherichia, PhoA signal sequence, OmpA signal sequence, etc .; if the host is Bacillus ⁇ -amylase signal sequence, subtilisin signal sequence, etc. If the host is yeast, When the host is an animal cell, an insulin signal sequence, an ⁇ -interferon signal sequence, an antibody molecule signal sequence, etc. are used. '
- a transformant containing DNA encoding chsp60 or a partial peptide thereof can be produced by transforming a host with an expression vector containing the DNA according to a known method.
- the expression vector includes those described above.
- Escherichia bacteria for example, Escherichia bacteria, Bacillus bacteria, yeast, insect cells, insects, animal cells, and the like are used.
- Escherichia examples include, for example, Escherichia coli K12, DH1 [Procedures, Op., The National, Op. USA (Proc. Natl. Acad. Sci. USA), 60, 16 (1968)], JM 103 (Nucleic Acids Research, 9, 30) 9 (1 981)], JA 221 [Journal of Molecular Biology, Vol. 120, 5 17 (1 9 7 8)], HB 10 1 [Journal 'ob''molecular' bio For example, 41 volumes, 495 (1969), C600 [Genetics, 39 volumes, 440 (1954)] and the like are used.
- Bacillus bacteria examples include, for example, Bacillus subtilis MI114 (Gene, 24, 255 (1983)), 207—21 'Journal of Biochemistry, 95, Vol. 87 (1989)].
- yeast examples include, for example, Saccharomyces cerevisiae AH22, AH22R ", NA87-111A, DKD-5D, 2OB-12, Schizosaccharomyces bomb (Schizosaccharomyces bomb). 'pombe) NCYC 1913, N CYC 230 36, Pichia pastoris KM71 and the like are used.
- insect cells for example, when the virus is AcNPV, a cell line derived from a larva of night-moth (Spodoptera frugiperda cell; Sf cell),
- MG1 cells derived from the midgut of Trichoplusia ni, High Five TM cells derived from eggs of Trichoplusia ni, cells derived from Mamestra brassicae, cells derived from Estigmena acrea, and the like are used.
- viruses When the virus is BmNPV, a silkworm-derived cell line (Bombyx mori N cell; BmN cell) or the like is used as the insect cell.
- Sf cell include Sf9 cell (ATCC CRL1711) and Sf21 cell (Vaughn, JL et al., In Vivo, 13, 213-217, (1977) ) Is used.
- insects for example, silkworm larvae are used [Maeda et al., Nature, Vol. 3115, 592 (19985)].
- animal cells examples include monkey cells COS-7, V ero, Chinese hamster cell CHO (hereinafter abbreviated as CHO cell), dhfr gene-deficient Chinese hamster cell CHO (hereinafter abbreviated as CHO (dhfr ⁇ ) cell). ), Mouse L cell, mouse AtT—20, mouse myelo Mammal cells, rat GH3, human FL cells, etc. are used.
- Transformation can be performed according to a known method depending on the type of host.
- Escherichia bacterium is described, for example, in Proc. Natl. Acad. Sci. USA, Proc. Natl. Acad. Sci. USA, 69, 2 Transformation can be performed according to the method described in 110 (1972), Gene, Vol. 17, 107 (1982) and the like.
- Bacillus spp. Can be transformed, for example, according to the method described in Molecular & General Genetics, Volume 168, 11 (1979), etc. .
- Yeasts are described, for example, in Methods in Enzymology, Vol. 194, Vol. 182 — 187 (1991), Proceedings of the National Academy Op. Transformation can be performed according to the method described in Sciences of the USA, USA (Proc. Natl. Acad. Sci. USA), 75, 1929 (19778). Insect cells and insects are, for example, bio Z technology (
- the transformant can be cultured according to a known method depending on the type of the host.
- a liquid medium is preferable as the medium used for the culture.
- the medium preferably contains a carbon source, a nitrogen source, an inorganic substance, and the like necessary for growing the transformant.
- a carbon source for example, dalcose, dextrin, soluble starch, sucrose, etc .
- a nitrogen source for example, ammonium salts, nitrates, corn-like liquor, peptone, Inorganic or organic substances such as casein, meat extract, soybean meal, and potato extract
- examples of the inorganic substances include calcium chloride, sodium dihydrogen phosphate, and magnesium chloride.
- the medium may be supplemented with yeast extract, vitamins, growth promoting factors and the like. ⁇ of the medium is preferably about 5 to about 8.
- a medium for culturing a transformant whose host is a bacterium belonging to the genus Escherichia for example, a medium containing glucose and casamino acid can be used (for example, Miller, Miller, Gianna Leob 'Experiment'in'Molecular) 'Journal of Experiments in Molecular Genetics, 431-43, Cold Spring Harbor Laboratory, New York 1972].
- an agent such as 3j3-indolylacrylic acid may be added to the medium to make the promoter work efficiently.
- Culture of the transformant whose host is a bacterium belonging to the genus Escherichia is usually performed at about 15 to about 43 ° C. for about 3 to about 24 hours. Ventilation and agitation may be performed if necessary. Culture of the transformant whose host is a bacterium belonging to the genus Bacillus is usually performed at about 30 to about 40 ° C for about 6 to about 24 hours. If necessary, ventilation or stirring may be performed.
- a culture medium for culturing a transformant in which the host is yeast for example, a minimal medium (Burkholder) [Bostian, KL et al., Proc. Onethings Op The Nashinanore Academy Academy Of Sciences' Ob The USA (Proc. Natl. Acad. Sci. USA), 77, 4500 (1980) ] Or an SD medium containing 0.5% casamino acid [Bitter, GA et al., Processing of the National Academy of Sciences Opus USA (Proc. Natl. Acad. Sci. USA), 81 volumes, 5330 (1994)].
- the pH of the medium is preferably from about 5 to about 8.
- the cultivation is usually performed at about 20 ° C. to about 35 ° C.
- a medium for culturing a transformant in which the host is an animal cell for example, a MEM medium containing about 5 to about 20% fetal bovine serum [Science, Volume 122, Volume 501] (1952)], DMEM medium [Virology, 8 vol., 39 (1959)], RPMI 1640 medium [Journal of the medium] '' Medical Association (The Journal of the American Medical Association No. 9: ,, 5 19 (1 9 6 7)), 19 9 Medium [Proceding of the Society for the No. Physiological Medicine (Proceeding of the Society for the Biological Medicine), Volume 73, 1 (1950)], etc.
- the pH of the medium is preferably about 6 to about 8. It is usually carried out at about 30 ° C. to about 40 ° C. for about 15 to about 60 hours. Or stirring may be performed. '
- chspSO or a partial peptide thereof or a salt thereof can be produced in the cell, in the cell membrane, or outside the cell of the transformant.
- Chsp60s can be separated and purified from a culture obtained by culturing the transformant according to a method known per se.
- the culture, the bacteria or cells are collected by known methods from suspended in a suitable buffer, ultrasound, lysozyme and / or freeze-thaw, etc. After the cells or cells are destroyed by the method described above, a method of obtaining a crude extract of the protein by centrifugation or filtration is used as appropriate.
- the buffer may contain a protein denaturing agent such as urea or guanidine hydrochloride, or a surfactant such as Triton X-100 TM.
- proteins (peptides) are secreted into the culture solution, a method of collecting the culture supernatant from the culture by a known method is used.
- the protein (peptide) contained in the culture supernatant or extract obtained in this manner can be purified by a method known per se.
- Such methods include methods using solubility such as salting out and solvent precipitation; mainly using differences in molecular weights such as dialysis, ultrafiltration, gel filtration, and SDS-polyatarylamide gel electrophoresis.
- a method utilizing a difference in charge such as ion exchange chromatography; a method utilizing a specific affinity such as affinity chromatography; a method utilizing a difference in hydrophobicity such as reverse phase high performance liquid chromatography.
- a method utilizing a difference in isoelectric point such as isoelectric focusing electrophoresis; and the like. These methods can be appropriately combined.
- affinity chromatography In order to purify the recombinant chsp60s more quickly and easily, it is preferable to use affinity chromatography.
- an anti-chsp60 antibody column As the affinity column, an anti-chsp60 antibody column can be used. If a suitable tag sequence (eg, His tag, GST tag, MBP tag, etc.) is added to the DNA encoding the partial peptide, a metal ion chelate, glutathione, maltose immobilized column Etc. can be used as appropriate.
- a metal ion chelate, glutathione, maltose immobilized column Etc. can be used as appropriate.
- Both monoclonal antibodies and polyclonal antibodies against chsp60 are commercially available (eg, manufactured by Amersham) or a method for producing an antibody or antiserum known per se using chsp60s as an antigen (for example,- : See below).
- the free form can be converted into a salt by a method known per se or a method analogous thereto, and the protein (peptide) is converted into a salt.
- the salt can be converted to a free form or another salt by a method known per se or a method analogous thereto.
- the protein (peptide) produced by the transformant can be arbitrarily modified or the polypeptide can be partially removed by applying an appropriate protein-modifying enzyme before or after purification.
- an appropriate protein-modifying enzyme for example, trypsin, chymotrypsin, arginyl endopeptidase, protein kinase, glycosidase and the like are used.
- trypsin, chymotrypsin, arginyl endopeptidase, protein kinase, glycosidase and the like are used.
- the presence of the thus obtained chsp60s can be confirmed by soil blotting using specific antibodies.
- Chsp60 such is the RNA corresponding to the DNA encoding the above chs P 60 or a partial peptide thereof as an ⁇ , that Do the like Usagi reticular erythrocyte lysate, wheat germ lysate, Escherichia coli lysate
- In vitro synthesis can be performed using a cell-free protein translation system.
- a cell-free transcription / translation system containing RNA polymerase the DNA encoding chsp60 or a partial peptide Can also be synthesized.
- the cell-free protein (transcription) translation system a commercially available one can be used, or a method known per se, specifically, E.
- coli extract can be obtained from Pratt JM et al., Transcription and Tranlation, 179-209, Hames BD & Higgins SJ eds., IRL Press, Oxford (1984). It is a commercially available cell lysate, derived from E. coli or E. coli S30 extract system (Promega Corp.) - RTS 500 Rapid Tranlation System ( Roche Co.) Hitoshiryoku S include, 1 from Usagi reticulocytes Rabbit Reticulocyte Lysate System (Promega) and the like, and those derived from wheat germ include PR0TEIOS TM (TOYOBO). Among them, those using a wheat germ lysate are preferred.
- Methods for preparing wheat germ lysates include, for example, Johnston FB et al., Nature, 179, 160-161 (1957), and Erickson AH et al., Meth. Enzymol., 96, 38-50 (1996). ) Etc. can be used.
- Examples of the system or apparatus for protein synthesis include a batch method (Pratt, JM et al. (1984), supra) and a continuous cell-free system that continuously supplies amino acids, energy sources, etc. to the reaction system.
- Protein synthesis system (Spirin AS et al., Science, 242, 1162-1164 (1988)), dialysis method (Kikawa et al., 21st Annual Meeting of the Molecular Biology Society of Japan, WID6), or multi-layer method (PR0TEI0S TM Wheat germ cell-free) manual for protein synthesis core kit) (manufactured by TOYOBO).
- a method of supplying a type II RNA, an amino acid, an energy source, and the like to the synthesis reaction system as needed, and discharging a synthesized product and a decomposed product as needed JP-A-2000-333673 can be used.
- chsp60s can be provided not only as an isolated protein (peptide) but also in the form of a cell capable of producing it.
- the cells capable of producing chs P 60 include, in addition to various strains belonging to Kuramijia pneumoniae that produce chsp60 naturally, artificially chs P 60 such the have been engineered to produce cells, for example, and the chsp60 Or a transformant containing DNA encoding the partial peptide.
- the transformant is capable of producing chsp60 in an amount sufficient to enhance MMP-9 expression in the cell line under conditions suitable for culturing a monocyte cell line.
- the cells capable of producing chsp60s include various strains belonging to Chlamydia pneumoe, particularly preferably the above-mentioned KKpn-1 strain.
- the monocyte cell line used in the present invention is not particularly limited as long as it is a cell line established from monocytes or macrophages derived from mammals, and known monocyte cell lines (for example, ⁇ _ 1, U-93, ⁇ 31 / FUJ, mouse monocyte-derived R AW 264.7, J774A.1, etc.), as well as mammals Cells of cell lines newly established by establishing monocytes or macrophages isolated from E. coli using known culture techniques are also included.
- Monocyte-based cell lines include monocytes and macrophages isolated from mammals such as humans, and monocyte-based cells such as primary macula phages differentiated from monocytes using differentiation-inducing factors such as GM-CSF. as compared to the primary cell, the degree of ⁇ P- 9 enhanced expression by chs P 60 stimulation significantly higher. Therefore, there is an advantage that a more sensitive screen-jung system can be provided. Desirably, the expression of the MMP-9 gene when stimulated with ⁇ ⁇ ⁇ ch chsp60s for 48 hours is 5 times or more, preferably 10 times or more, more than that of the case where no stimulation is performed with chsp60s A 20-fold or more monocyte cell line is used.
- the monocyte cell line is a cell of a cell line such as THP-1, U-937, P31 / FUJ derived from human monocyte, and particularly preferably, a THP-1 cell line. Cells.
- Monocyte cell lines are prepared using a culture medium suitable for each cell [for example, minimal essential medium (MEM) supplemented with fetal calf serum or antibiotics (penicillin, streptomycin, etc.), Dulbecco's modified, if desired. Eagle's medium (DMEM), RPMI 164 medium, 199 medium, F12 medium, etc.].
- MEM minimal essential medium
- DMEM Dulbecco's modified, if desired.
- RPMI 164 medium 199 medium, F12 medium, etc.
- the screening method of the present invention measures and compares the expression of MMP-9 gene under both conditions when a monocyte cell line is stimulated with chsp60s in the presence and absence of a test compound. It is characterized by the following.
- the stimulation by chsp60s can be appropriately selected according to the form of the provided chsp60s. That is, when chs P 60 such that an isolated protein (peptide), monocytic was dissolved in the chs P 60 such a predetermined concentration KabukaHoso ⁇ culture (e.g., see above)
- the incubation can be carried out by incubating the monocytic cell line with E. coli.
- the concentration of chsp60s is about 100 to about 100 nM (about 5 to about 80 / zg / ml when using chsp60), preferably about 200 to about 400 nM.
- No. Incubation can be carried out using a culture vessel used for culturing animal cells.
- a 96-well plate is preferably used.
- the cell density is, for example, about 5 ⁇ 10 5 to about 1 ⁇ 10 6 cells / ml.
- Fin incubation for example, C_ ⁇ 2 Lee incubator: during (eg 5% C_ ⁇ 2, 95% air), from about 4 0 to about 7 2 hours at about 3 0 to about 4 0 ° C, preferably About 44 to about 50 hours can be performed.
- the chsp60 compound is provided in the form of cells capable of producing it, by fin incubation the monocytic cell line under coexistence of the cell, stimulating the cell line in chs P 60 such can do.
- the added amount of cells capable of producing chsp60s may be any amount that can provide the same stimulation as that stimulated by the above concentration of chsp60s.
- the added amount of cells capable of producing chsp60s may be any amount that can provide the same stimulation as that stimulated by the above concentration of chsp60s.
- Chsp60 such producing cells may be a monocytic KabukaHoso 1 ⁇ body.
- a transformant obtained by transforming a monocyte cell line as a host cell with an expression vector containing DNA encoding chsp60 or a partial peptide thereof according to the method described above can be performed by incubation under the same conditions as described above.
- the transformant is more preferred to be manipulated so that resulting produced only under predetermined conditions the chs P 60 such.
- a method for preparing such a transformant include, for example, expression in which DNA encoding chsp60 or a partial peptide thereof is placed under the control of an inducible native promoter (eg, a metallotionin promoter, a heat shock promoter, etc.). Examples include a method using a vector and a method using a CRE-loxP system.
- stimulation with chsp60s refers to the time when an inducer (or induction stress) is applied
- non-stimulation refers to the time when chsp60s expression is not induced.
- test compound used for screening of the compound for example, a compound library prepared using combinatorial chemistry technology, a run prepared by solid phase synthesis or phage display method. Dam peptide library, or natural components derived from microorganisms, animals, plants, marine organisms and the like.
- the method for measuring the expression of the marauding P-9 gene in a monocyte cell line is not particularly limited. For example, using a nucleic acid containing a nucleotide sequence encoding MMP-9 or a part thereof as a probe, and performing RNA hybridization extracted from the cell line as type ⁇ , or performing P-9 coding
- a synthetic oligo-DNA containing a part of the salt-base sequence as a primer and performing quantitative RT-PCR using RNA extracted from the cell line as a type II, gene expression at the RNA level can be achieved. The amount can be measured.
- the nucleic acid containing the base sequence encoding MMP-9 or a part thereof includes, for example, the base sequence represented by SEQ ID NO: 3 or a base sequence that can hybridize with the base sequence under conditions of high stringency. Nucleic acids are listed.
- the nucleic acid may be DNA or RNA, or a DNA / RNA chimera.
- the nucleic acid may be single-stranded or double-stranded, and if single-stranded, may be a sense strand or an antisense strand. In the case of a double-stranded DNA, it may be a DNA: RNA hybrid.
- expression of the MMP-9 gene can be performed at the protein level using a conventional Imno-Assy system using an anti-MMP-9 antibody.
- the anti-MMP-9 antibody used here may be a monoclonal antibody or a polyclonal antibody.
- F (ab,) 2 , Fab ', Fab fraction, etc. Can also be used.
- P-9 MMP-9 or its partial peptide or salt thereof (sometimes referred to as J) can be used as an antigen in accordance with a known method for producing an antibody or antiserum.
- the protein is preferably, but not limited to, a protein of the same origin as the monocyte cell line used for screening.
- MMP-9s are purified from MMP-9-producing cells (eg, monocytes derived from mammals, macrophages, etc.) using a known protein separation technique, or represented by SEQ ID NO: 4.
- Monoclonal and polyclonal antibodies to MMP-9 can be prepared, for example, as follows.
- MMP-9s are administered to a warm-blooded animal to a site where the antibody can be produced upon administration, by itself or together with a carrier or diluent.
- Complete Freund's adjuvant or incomplete Freund's adjuvant may be administered in order to enhance antibody production during administration. Administration is usually performed once every 2 to 6 weeks, for a total of about 2 to 10 times.
- Examples of the warm-blooded animal used include mammals such as monkeys, rabbits, rabbits, dogs, monoremots, mice, rats, sheep, goats, and the like (and birds other than mammals). , Mice and rats are preferably used.
- a warm-blooded animal immunized with an antigen such as a mouse
- an antigen such as a mouse
- the spleen or lymph node is collected 2 to 5 days after the final immunization.
- a monoclonal antibody-producing hybridoma can be prepared by collecting the cells and fusing the anti-producing cells contained therein with myeloma cells of the same or different species.
- the antibody titer in the antiserum can be measured, for example, by reacting the labeled protein described below with the antiserum, and then measuring the activity of the labeling agent bound to the antibody.
- the fusion operation can be performed according to a known method, for example, the method of Kohler and Minorestein (Nature, 256, 495 (1975)).
- the fusion promoter include polyethylene glycol (PEG) and Sendai virus, but PEG is preferably used.
- PEG polyethylene glycol
- myeloma cells include myeloma cells of warm-blooded animals such as NS-1, P3U1, SP2 / 0, and AP-1, but P3U1 is preferably used. .
- the preferred ratio between the number of antibody-producing cells (spleen cells) and the number of myeloma cells to be used is about 1: 1 to 20: 1, and the PEG (preferably PEG100 to PEG600) power 1 It is added at a concentration of about 0-80% and at 20-40 ° C, preferably at 30-37 ° C :! By incubating for ⁇ ⁇ 10 minutes, cell fusion can be carried out efficiently.
- Monoclonal antibody-producing hybridomas are obtained, for example, by adding a hybridoma culture supernatant to a solid phase (eg, a microplate) on which a protein antigen is adsorbed directly or together with a carrier, and then labeling with a radioactive substance or an enzyme.
- a solid phase eg, a microplate
- Anti-globulin antibody (if mouse cells are used for cell fusion, anti-mouse immunoglobulin purine antibody is used) or protein A, and monoclonal antibody bound to solid phase is detected; anti-immunoglobulin antibody A method in which the hybridoma culture supernatant is added to the solid phase to which the antibody or protein A is adsorbed, a protein labeled with a radioactive substance, an enzyme, or the like is added, and the monoclonal antibody bound to the solid phase is detected. You can sing. Selection of the monoclonal antibody can be carried out according to a method known per se or a method analogous thereto.
- Monoclonal antibodies can usually be selected in a medium for animal cells supplemented with HAT (hypoxanthine, aminopterin, thymidine).
- HAT hyperxanthine, aminopterin, thymidine
- any medium can be used as long as hybridomas can grow.
- Such a medium is, for example, 1 to 20%, preferably 10 to 20%.
- RPMI 1640 medium containing fetal calf serum 1 to: GIT medium containing 10% fetal calf serum (Wako Pure Chemical Industries, Ltd.) or a hybrid serum-free medium (SFM-1) 01, Nissui Pharmaceutical Co., Ltd.).
- the culture temperature is usually 20 to 40 ° C, preferably about 0.37 ° C.
- the culturing time is usually 5 days to 3 weeks, preferably 1 week to 2 weeks.
- the culture can be usually performed under 5% carbon dioxide.
- the antibody titer of the hybridoma culture supernatant can be measured in the same manner as the measurement of the antibody titer in the antiserum described above.
- the monoclonal antibody thus obtained can be obtained by a method known per se, for example, an immunoglobulin separation and purification method [eg, salting out method, alcohol precipitation method, isoelectric point precipitation method, electrophoresis method, ion exchanger, (E.g., DEAE) adsorption / desorption method, ultracentrifugation method, gel filtration method, antigen-bound solid phase or only antibody is collected using an active adsorbent such as protein A or protein G, and the bond is dissociated to release the antibody.
- an immunoglobulin separation and purification method eg, salting out method, alcohol precipitation method, isoelectric point precipitation method, electrophoresis method, ion exchanger, (E.g., DEAE) adsorption / desorption method, ultracentrifugation method, gel filtration method, antigen-bound solid phase or only antibody is collected using an active adsorbent such as protein A or protein G, and the bond is dissociated to release the
- a polyclonal antibody against MMP-9 can be produced according to a method known per se.
- an immune antigen protein antigen itself or a complex thereof with a carrier protein is formed, and immunization is performed on a warm-blooded animal in the same manner as in the above-described monoclonal antibody production method. It can be manufactured by collecting antibody-containing substances and separating and purifying the antibodies. it can.
- the type of carrier protein and the mixing ratio of carrier and hapten are determined by the efficiency of the antibody against the hapten immunized by cross-linking the carrier. If possible, any kind may be cross-linked at any ratio.For example, ⁇ serum albumin ⁇ ⁇ cysteine oral globulin, hemocyanin, etc. may be used in a weight ratio of 0.1 to 20 with respect to 1 hapten. Preferably, a method of coupling at a ratio of 1 to 5 is used.
- an active ester reagent containing an active ester, maleimide active ester, thiol, or dithioviridyl group are used for the hapten and carrier force ring.
- the condensation product is administered to a warm-blooded animal itself or together with a carrier and a diluent at a site where antibody production is possible.
- Complete Freund's adjuvant or incomplete Freund's adjuvant may be administered in order to enhance the antibody-producing ability upon administration.
- the administration is usually performed once every 2 to 6 weeks, for a total of about 3 to 10 times.
- the polyclonal antibody can be collected from the blood, ascites, etc., preferably from the blood of a warm-blooded animal immunized by the above method.
- the measurement of the polyclonal antibody titer in the antiserum can be performed in the same manner as the measurement of the antibody titer in the antiserum described above. Separation and purification of the polyclonal antibody can be performed according to the same method for separation and purification of immunoglobulin as in the above-described separation and purification of monoclonal antibody.
- the method for quantifying MMP-9 or a salt thereof using an anti-MMP-9 antibody is not particularly limited, and the amount of the antibody, antigen or antibody-antigen complex corresponding to the amount of antigen in the test solution is measured.
- Any measurement method may be used as long as it is a measurement method calculated from a standard curve prepared using a standard solution containing a known amount of antigen.
- the anti-p-9 antibody is allowed to react competitively with the test solution (culture supernatant after incubation) and the labeled banded P-9s, and the labeled antibody bound to the antibody is reacted. Quantification of MMP-9 or its salt in the test solution by measuring the proportion of the MMP-9 class (competition method), and
- one antibody is an antibody that recognizes the N-terminal of MMP-9
- the other antibody recognizes the other part of P-9, such as the C-terminal Desirably, it is an antibody.
- a labeling agent used in a measurement method using a labeling substance for example, a radioisotope, an enzyme, a fluorescent substance, a luminescent substance and the like are used.
- the radioisotope for example, [ 125 I], [ 131 I], [ 3 H], [ 14 C] and the like are used.
- the enzyme a stable enzyme having a large specific activity is preferable.
- the fluorescent substance for example, fluorescamine, fluorescein isothiocyanate and the like are used.
- the luminescent substance for example, luminol, luminol derivative, luciferin, lucigenin and the like are used.
- the binding of antibody or antigen to the labeling agent is
- Avidin systems can also be used.
- the carrier include insoluble polysaccharides such as agarose, dextran, and cellulose; synthetic resins such as polystyrene, polyacrylamide, and silicon; and glass.
- the test solution is reacted with the insolubilized anti-P- 9 antibody (primary reaction), and then reacted with another labeled anti-MMP-9 antibody (secondary reaction).
- primary reaction By measuring the activity of the labeling agent on the carrier, the amount of MMP-9 or a salt thereof in the test solution can be determined.
- the primary reaction and the secondary reaction may be performed in the reverse order, may be performed simultaneously, or may be performed at staggered times.
- the labeling agent and the method of insolubilization can be the same as those described above.
- the antibody used for the immobilized antibody and the labeled antibody does not necessarily need to be one kind, and a mixture of two or more kinds of antibodies is used for the purpose of improving measurement sensitivity and the like. May be used.
- an anti-P-9 antibody used in the primary reaction and the secondary reaction is preferably an antibody having a different binding site to MMP-9.
- the antibody used in the secondary reaction recognizes the C-terminal of band P-9
- the antibody used in the primary reaction is preferably used. Is an antibody that recognizes other than the C-terminal, for example, the N-terminal.
- the anti-P_9 antibody can also be used in a measurement system other than the sandwich method, for example, a competition method, an immunometric method, or a nephelometry.
- a competition method the antigen in the test solution and the labeled antigen are used for the antibody.
- the unreacted labeled antigen (F) and the labeled antigen (B) bound to the antibody are separated (BZF separation), the amount of either B or F label is measured, and the amount of Quantify the amount of antigen.
- a soluble antibody is used as the antibody
- BZF separation is performed using polyethylene glycol
- a solid phase antibody is used as the primary antibody.
- a solid-phase method using a soluble primary antibody and a solid-phased antibody as a secondary antibody is used.
- the liquid phase method it is possible to use homogeneous immonoassays such as surface plasmon resonance, fluorescence polarization imnoassay, fluorescence quenching imnoassay, and fluorescence energy transition imnoassay.
- an antigen in a test solution and a solid-phased antigen are subjected to a competitive reaction with a fixed amount of a labeled antibody, and then a solid phase and a liquid phase are separated.
- the antigen in the solution is allowed to react with an excessive amount of the labeled antibody, and then a solid-phased antigen is added to bind the unreacted labeled antibody to the solid phase. Then, the solid phase and the liquid phase are separated. Next, the amount of label in either phase is measured to determine the amount of antigen in the test solution.
- nephelometry the amount of insoluble sediment resulting from an antigen-antibody reaction in a gel or in a solution is measured. Even when the amount of antigen in the test solution is small and only a small amount of sediment is obtained, laser nephelometry utilizing laser scattering is preferably used.
- An MMP-9 measurement system may be constructed by adding ordinary technical considerations to those skilled in the art to the ordinary conditions and operation methods in each method. For details of these general technical means, reference can be made to reviews, written documents, and the like.
- the expression of the MMP-9 gene can be measured using the enzyme activity of the produced MMP-9 or a salt thereof as an index.
- the method for measuring the enzyme activity is not particularly limited.
- a test solution (culture supernatant after incubation is completed) may be gel-containing an MMP- 9 substrate (eg, gelatin, type IV collagen, etc.). , SDS—polyacrylamide gel, etc.), remove the SDS, refold MMP-9, incubate the gel in an appropriate buffer—and adjust the concentration of the dissolving band. Quantification by image analysis.
- the method for measuring the expression of the P-9 gene is to competitively react the test solution and the enzyme-labeled thigh P-9s with an anti-Mandarial P-9 antibody. This is a competitive ELISA method.
- results of the above measurement of MMP- 9 gene expression for example, chs P 60 stimulation during MMP- 9 expression level of a gene about 2 0% or more, preferably 3 0% or more, more preferably Can be selected as compounds that inhibit the induction of MMP-9 expression by chsp60.
- the compound that inhibits the induction of expression of the fraction P-9 selected as described above is a plaque that inhibits the increase in secretion of MMP-9 from foam cells derived from Mac mouth phage vascular smooth muscle cells due to Cp infection. It is effective for the treatment of arteriosclerosis and / or the prevention and treatment of its complications, because it can prevent the fibrous cap from weakening and prevent the plaque from destabilizing and breaking down.
- the present invention also provides a kit suitable for performing the above-described screening method.
- the screening kit of the present invention is characterized by comprising a monocyte lineage cell line and a chsp60 or a cell capable of producing the same, or an expression vector containing a DNA encoding the same.
- the monocyte cell line and the chsp60s or cells capable of producing the same or the expression vector containing the DNA encoding the same are as described above in the description of the screening method of the present invention. Can be used.
- the screening kit of the present invention comprises a monocyte cell line engineered to produce chsp60s.
- a monocyte cell line those described above in the description of the screening method of the present invention can be used.
- the screening kit of the present invention may further contain reagents for measuring the expression of the MMP-9 gene.
- the kit can further include, for example, sense and antisense primers capable of amplifying a fragment of MMP-9 RNA.
- the base sequence of the primer pair include the above-mentioned Vehmaan-Kreula, P. et al., Arterioscler. Throrab. Vase. Biol. (USA), 2001, Vol. 21, pp. E1—e Examples include, but are not limited to, the primers described in No.
- nucleotide sequence of a nucleic acid encoding MMP-9 (eg, For example, based on the base sequence represented by SEQ ID NO: 3), another suitable primer can be easily constructed using known primer design support software as necessary.
- the kit further contains an anti-MMP-9 antibody and an enzyme-labeled MMP-9 or a partial peptide thereof or a salt thereof.
- an anti-MMP-9 antibody and the enzyme-labeled MMP-9 those described above in the description of the screening method of the present invention can be used.
- the kit further comprises a secondary antibody capable of specifically recognizing the anti-P-9 antibody (primary antibody) (for example, when the primary antibody is a rabbit-derived anti-femoral P-9 IgG antibody, a goat-derived anti-Peagle IgG).
- the present invention also provides an agent for treating arteriosclerosis and preventing or treating Z or its complications, comprising a substance capable of suppressing the induction of MMP-9 gene expression in mammalian cells by chsp60.
- the prophylactic or therapeutic agent can contain a pharmacologically acceptable carrier as needed.
- the “pharmacologically acceptable carrier” various organic or inorganic carrier substances commonly used as pharmaceutical materials are used, and excipients, lubricants, binders, disintegrants in solid preparations; Formulated as a solvent, solubilizer, suspending agent, tonicity agent, buffer, soothing agent, etc. in liquid preparations. If necessary, pharmaceutical additives such as preservatives, antioxidants, coloring agents and sweeteners can also be used.
- excipients include lactose, sucrose, D-mantol, D-sorbitol, starch, ⁇ ; modified starch, dextrin, crystalline cellulose, low-substituted hydroxypropynolecellulose, and carboxymethyl.
- Senorelose sodium, arabia gum, dextrin, pullulan, light caffeic anhydride examples include synthetic aluminum silicate and magnesium metasilicate.
- lubricant examples include magnesium stearate, calcium stearate, talc, colloid silica and the like.
- Preferred examples of the binder include pregelatinized starch, sucrose, gelatin, arabia gum, methinoresenorelose, carboxymethylsenorelose, sodium carboxymethinoresenorelose sodium, crystalline senorelose, and sucrose. , D-mannonitrile, trenoperose, dextrin, punorelane, hydroxypropinolesenololose, hydroxypropinolemethinoresenorelose, polyvinylinolepyrrolidone and the like.
- disintegrants include lactose, sucrose, starch, carboxymethinoresenorelose, force / repoxymethinoresenolaceroscanolecum, closcanoremerose sodium, carboxymethyl starch sodium, light anhydrous kerosene. Acid, low-substituted hydroxypropylcellulose and the like.
- Preferred examples of the solvent include water for injection, physiological saline, Ringer's solution, phenolic cornole, propylene glycol cornole, polyethylene glycol cornole, sesame oil, corn oil, olive oil, cottonseed oil and the like.
- solubilizing agent examples include polyethylene dalicol, propylene glycol cornole, D-mannitonole, tre /, loin, benzinole benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, and sodium carbonate. Lithium, sodium citrate, sodium salicylate, sodium acetate and the like.
- the suspending agent include surfactants such as stearyltriethanolamine, sodium radium sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate.
- surfactants such as stearyltriethanolamine, sodium radium sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate.
- polyvinyl alcohol, polyvinylpyrrolidide Hydrophilic polymers such as sodium, canolepoxymethinoresenorelose, sodium methinoresenorelose, hydroxoximethinoresenorelose, hydroxyxetinoresenorelose, and hydroxypropyl pill cellulose; polysorbate And polyoxyethylene hardened castor oil.
- the tonicity agent include sodium chloride, glycerin, D-mannitol, D-sorbitol, glucose and the like.
- buffers such as phosphate, acetate, carbonate, and citrate.
- Preferred examples of the soothing agent include benzyl alcohol and the like.
- Preferable examples of the preservative include paraoxybenzoic acid esters, black alcohol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, and sorbic acid.
- Suitable examples of the antioxidant include sulfite and ascorbate.
- Suitable examples of the coloring agent include water-soluble edible tar dyes (eg, edible dyes such as edible red Nos. 2 and 3, edible yellows 4 and 5, edible blue Nos. 1 and 2), water-insoluble lake dyes (Eg, the aluminum salt of the water-soluble edible tar dye, etc.), and natural pigments (eg, j3-carotene, chlorophyll, bengalara, etc.).
- water-soluble edible tar dyes eg, edible dyes such as edible red Nos. 2 and 3, edible yellows 4 and 5, edible blue Nos. 1 and 2
- water-insoluble lake dyes Eg, the aluminum salt of the water-soluble edible tar dye, etc.
- natural pigments eg, j3-carotene, chlorophyll, bengalara, etc.
- sweetener examples include sodium saccharin, sodium potassium glycyrrhizinate, aspartame, stevia and the like.
- Examples of the dosage form of the pharmaceutical composition include oral preparations such as tablets, capsules (including soft capsules and microcapsules), granules, powders, syrups, emulsions, and suspensions; , Subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, etc.), external preparations (eg, intranasal preparations, transdermal preparations, ointments, etc.), suppositories (eg, rectal suppositories, Vaginal suppositories), pellets, Parenteral preparations such as drops and sustained-release preparations (eg, microrelease capsules) can be safely orally or parenterally administered, respectively.
- oral preparations such as tablets, capsules (including soft capsules and microcapsules), granules, powders, syrups, emulsions, and suspensions
- Subcutaneous injections eg, intravenous injections, intramuscular injections, intraperitoneal injections, etc.
- the pharmaceutical composition can be produced by a method commonly used in the technical field of formulation, for example, a method described in Japanese Pharmacopoeia. Hereinafter, the specific production method of the drug product will be described in detail.
- the content of the compound obtained by the screening method of the present invention in the pharmaceutical composition varies depending on the dosage form, the dose of the compound and the like, and is, for example, about 0.1 to 100% by weight.
- oral preparation the active ingredient, an excipient (e.g., lactose, sucrose, starch, D- mannitol), disintegrating ⁇ (e.g., such as carboxymethylcellulose force Rushiumu), binders (e.g., alpha starch, Gum arabic, carboxy simethinoresenololose, hydroxypropinoresenololose, polyvinylinolepyrrolidone, etc.) or lubricants (eg, talc, magnesium stearate, polyethylene dalicol 600, etc.) It is produced by compression molding and then, if necessary, coating with a coating base in a manner known per se for the purpose of taste masking, enteric coating or persistence. ,
- excipient e.g., lactose, sucrose, starch, D- mannitol
- disintegrating ⁇ e.g., such as carboxymethylcellulose force Rushiumu
- binders e.g., alpha starch, Gum arab
- the coating base examples include a sugar coating base, a water-soluble film coating base, an enteric film coating base, and a sustained release film coating base. .
- sucrose is used, and one or more kinds selected from talc, precipitated calcium carbonate, gelatin, gum arabic, pullulan, carnauba wax and the like may be used in combination.
- Water-soluble film-coating bases include, for example, cenorelose such as hydroxypropinoresenorelose, hydroxypropinolesmethinoresenorelose, hydroxysechinoresenorelose, and methinoleshydroxechinoresenorelose.
- cenorelose such as hydroxypropinoresenorelose, hydroxypropinolesmethinoresenorelose, hydroxysechinoresenorelose, and methinoleshydroxechinoresenorelose.
- Polymers synthetic polymers such as polybutylacetal getylaminoacetate, aminoalkyl methacrylate copolymer E (Eudragit E (trade name), Koutum Pharma Co., Ltd.), polyvinylpyrrolidone, etc .; Sugars and the like.
- Enteric film coating bases include, for example, hydroxypine pinolemethinoresenolerose phthalate, hydroxypropinolemethinoresolenole-s-acetate succinate, canoleboximetinoletinol cellulose, and acetic acid.
- Senololose-based polymers such as cellulose phthalenolate; Copolymer meta-atalinoleate L (Eudragit L (trade name), Rohm Pharma Co., Ltd.); methacrylic acid copolymer LD [Eudragit L_30D55 (trade name) , Rohm Pharma Co., Ltd.), methacrylic acid copolymers
- sustained-release film coating base examples include cellulosic polymers such as ethyl cellulose; aminoalkyl methacrylate copolymer—RS (Eudragit RS (trade name), Rohm Pharma Co., Ltd.); Acrylic acid-based polymers such as ethyl acid / methyl methacrylate copolymer suspension [Eudragit NE (trade name), Rohm Pharma Co., Ltd.] and the like.
- cellulosic polymers such as ethyl cellulose; aminoalkyl methacrylate copolymer—RS (Eudragit RS (trade name), Rohm Pharma Co., Ltd.); Acrylic acid-based polymers such as ethyl acid / methyl methacrylate copolymer suspension [Eudragit NE (trade name), Rohm Pharma Co., Ltd.] and the like.
- the above-mentioned coating bases may be used by mixing two or more kinds thereof at an appropriate ratio.
- a light-shielding agent such as titanium oxide or iron trioxide may be used.
- Injectables contain active ingredients as dispersants (eg, polysorbate 80, polyoxyethylene hydrogenated castor oil 60, etc., polyethylene glycol, carboxymethyl cellulose, sodium alginate, etc.), and preservatives (eg, methyl paraben, propinorenol).
- dispersants eg, polysorbate 80, polyoxyethylene hydrogenated castor oil 60, etc., polyethylene glycol, carboxymethyl cellulose, sodium alginate, etc.
- preservatives eg, methyl paraben, propinorenol
- isotonic eg, sodium chloride, glycerin, D-mannitol, D-sorbitol, pudose, etc.
- aqueous solvents e.g, sodium chloride, glycerin, D-mannitol, D-sorbitol, pudose, etc.
- oily solvents e.g., vegetable oils such as olive oil, sesame oil, cottonseed oil, corn oil, propylene glycol, etc.
- additives such as a solubilizing agent (eg, sodium salicylate, sodium acetate, etc.), a stabilizer (eg, human serum albumin, etc.), a soothing agent (eg, benzyl alcohol, etc.) are added. May be used.
- the injection solution is usually filled in a suitable ampoule. ''
- the preparations obtained in this way are safe and low toxic and can be used, for example, in mammals (e.g., humans, mice, It can be administered orally or parenterally to monkeys, chimpanzees, etc.).
- the dosage of the prophylactic / therapeutic agent varies depending on the target disease, the severity, the administration target, the administration route, and the like. For example, in an adult patient (at a weight of 6 O kg) suffering from atherosclerosis, Is about 0.1 to about 100 mg per day, preferably about 1.0 to about 50 mg, and more preferably about 1.0 to about 100 mg per day as an active ingredient. 0 to about 20 mg, and this amount can be administered once or in several divided doses.
- bases, amino acids, and the like are indicated by abbreviations based on each of the items B by IUPAC-IUB.Communication on Biochemical Nomenclature or abbreviations commonly used in the art, and examples thereof are described below.
- amino acids can have optical isomers, the L-form is indicated unless otherwise specified.
- DNA Deoxylily; ⁇ Nucleic acid
- R N A Ribonucleic acid
- RNA Messenger ribonucleic acid
- dATP Deoxyadenosine triphosphate
- dTTP Deoxythymidine triphosphate
- dGTP Deoxyguanosine triphosphate
- dCTP Deoxycytidine triphosphate
- a 1 a Aranine
- a rg: Arginine H is: histidine
- sequence numbers in the sequence listing in the present specification show the following sequences.
- the base sequence of the DNA encoding chsp60 derived from Chlamydia pneumoniae KKpn-l strain is shown.
- nucleotide sequence of an oligonucleotide designed to function as a primer for amplifying DNA encoding chsp60 derived from Chlamydia pneumoniae KKpn-l strain is shown.
- Chlamydia pneumoniae KKpn-1 strain-derived DNA encoding chsp60 Shows the nucleotide sequence of an oligonucleotide designed to function as a primer for amplification.
- the genetic manipulation method described below is in accordance with the method described in a compendium (Maniatis et al., Molecular Closure, Cold Spring Harbor Laboratory, 1989) or the method described in the protocol attached to the reagent. 'I got it.'
- Cloning of chs P 60 gene was performed by PCR to ⁇ the DNA extracted from Cp-infected cells.
- HEp- 2 cells (approximately 2.5X 10 5 Ce lls / ml; Obtaining Dainippon Pharmaceutical Co., Ltd.) to inoculation plates (25cm 2 flask) 37 ° C at a carbon dioxide gas incubator, - after ⁇ culture, mono Discard the supernatant of the layer and transfer to Iscove's Modified Dulbecco's Medium (IMDM) medium (10% FBS, 100 ⁇ g / mL streptomycin, 50 ⁇ g / mL gentamicin, 0.5 g / mL cycloheximide).
- IMDM Iscove's Modified Dulbecco's Medium
- Cp Chlamydia * -Hum-moe (C p) KKpn-1 strain [Kishimoto T. and Soejima R., Intern. Med., 32: 934-937 (1993)] Cp was cultured by infecting -2. After culturing for 72 hours, the infected cells are collected with a cell scraper, washed twice with PBS, resuspended in 4 ml of TE buffer, and lysed by freeze-thawing three times at -80 ° C. The nucleic acid fraction obtained by phenol treatment and ethanol precipitation was used as type I for PCR.
- the ⁇ A fragment amplified above was digested with a restriction enzyme Ndel (Takara Shuzo), and the fragment was recovered by agarose gel electrophoresis. Its cut E. coli expression advance Ndel and DNA fragment plasmid pET21a (Obtaining:. N0VAGEN) were mixed, the DNA Ligation Kit Ver.2 (Takara Shuzo) was ligated in chs P 60 expression flop Rasumi de pHSP21_l Obtained. Escherichia coli BL21 (DE 3 ) is transformed with Escherichia coli using this plasmid.
- BL21 (DE3) / pHSP21-1 strain was obtained.
- This Escherichia coli strain was given the accession number of FERM BP-8430, and the Patented Organism Depositary (T305-A) was incorporated by the National Institute of Advanced Industrial Science and Technology (AIST) on July 16, 2003. 856'6 Tsukuba, Ibaraki Pref.
- Escherichia coli BL21 (DE3) / pHSP21-1 strain 1 white ear obtained in Reference Example 1 was inoculated into 1 L of seed culture medium (1% Tryptone, 0.5% Yeast Extract, 0.5% NaCl and 50 mg / L ampicillin). Then, seed culture was performed by culturing at 30 ° C.
- main culture medium (1.2% Tryptone, 2.4% Yeast Extract, 0, 2% Bactopeptone, 0.05% NaCl, 1.5% Glucose, 50 mg / L ampicillin and 50 mg / L Vitamin-Bl), and elapse 37 ° C, stirring 150rpm, air flow rate 20NL / tnin, dissolved oxygen concentration
- Main culture was started under the conditions of 2.0 ppm and pH control of 6.8.
- Cretu Titnit value X) 80 H reached Niommera ⁇ ; add Isopropyl ⁇ -D (-) -Thi oga lactopyranoside (IPTG) to a final concentration of ImM, and further 4 hours Expression of chsp60 was induced by culturing, and the expressed cells were recovered by centrifugation at 6000 rpm for 20 min.5 mM ethylenediaminetetraacetate sodium and ImM (p-amidinophenyl) methanesulfonyl fluoride were added to 350 g of the obtained cells.
- the eluate was replaced with 50 mM Tris / HC1 (pH 8.0) containing 2 M urea using ultrafiltration (PSU, 10k, Sartrius) and concentrated to obtain 2 L of concentrated solution.
- the eluate was passed through a Sephadex G-25 column (5 cm 'x 50 cm, Amersham Biosciences) equilibrated with Dulbecco's phosphate buffered saline solution, and 650 mL of the obtained ch.sp60 fraction was further added to the column.
- An Acticlean wheat iodine column (5 cm ⁇ 20 cm, Sterogene) equilibrated with Becko's phosphate buffered saline solution was used to remove endotoxin.
- the N-terminal amino acid sequence of purified chsp60 obtained in Reference Example 2 was The sequence was determined using a sequencer (Applied Biosystems, Model 492). As a result, except for the lack of the N-terminal amino acid Met of the obtained chsp60, the HSP60 derived from the Chlamydia pneumoe KKpn-1 strain deduced from the cDNA base sequence (SEQ ID NO: 1) was deleted. It was consistent with the N-terminal amino acid sequence.
- THP-1 cells a monocyte cell line, were purchased from American Type Culture Collection '(ATCC). IX 10 6 cells / mL THP_1 cell suspension prepared in RPMI 1640 medium (containing 100 / ig / mL streptomycin ⁇ 100umts / mL penicillin and 50g / mL gentamicin) supplemented with 1% fetal serum The prepared chsp60 was added at 20 ⁇ g / mL, and cultured under an environment of 5% CO 2 and 37 ° C. After 1, 2, and 3 days of culture, the culture supernatant is aspirated, and the amount of MMP-9 in the supernatant is measured.
- Example 2 monocyte system cell line IX 10 of 6 cells / mL THP- 1 cell suspension prepared in Reference Example 2 Chsp60 was added at 5, 10 or 20 ⁇ g / mL, and the cells were cultured in an environment of 5% CO 2 and 37 ° C. Two days after the culture, the culture supernatant was aspirated, and the amount of secreted P-9 in the supernatant was measured with an ELISA kit manufactured by Amersham. Culture in the same manner without adding chsp60 The culture supernatant of the obtained THP-1 cells was used as a control. The result is shown in figure 2. Induction of MMP-9 production increased in a concentration-dependent manner with chsp60.
- the screening method of the present invention uses a monocyte cell line to achieve higher MMP-9 expression compared to monocytes isolated from blood or primary macula phage.
- the screening method of the present invention uses a monocyte cell line to induce higher MMP-9 expression than monocytes isolated from blood or primary macula phage. It is effective as a highly sensitive screening system for a novel therapeutic agent for arteriosclerosis that can suppress the progression of arteriosclerosis due to Chlamydia 'pneumoniae infection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/570,971 US20060234297A1 (en) | 2003-09-09 | 2004-09-08 | Screening method |
EP04773069A EP1669446A4 (en) | 2003-09-09 | 2004-09-08 | SCREENING PROCESS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003316572 | 2003-09-09 | ||
JP2003-316572 | 2003-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005026348A1 true WO2005026348A1 (ja) | 2005-03-24 |
Family
ID=34308459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/013396 WO2005026348A1 (ja) | 2003-09-09 | 2004-09-08 | スクリーニング方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20060234297A1 (ja) |
EP (1) | EP1669446A4 (ja) |
WO (1) | WO2005026348A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008088864A2 (en) * | 2007-01-18 | 2008-07-24 | The Trustess Of Columbia University In The City Of New York | Matrix metalloproteinase-9-related methods |
WO2010036930A1 (en) * | 2008-09-26 | 2010-04-01 | Javad Parvizi | Methods and kits for detecting joint infection |
US20110097748A1 (en) * | 2009-10-28 | 2011-04-28 | Warsaw Orthopedic, Inc. | Use of cell lines to determine levels of efficacy of pharmaceutical formulations |
KR101829330B1 (ko) * | 2011-04-13 | 2018-02-20 | (주)아모레퍼시픽 | 염증성 피부 노화 억제 물질 스크리닝 방법 |
-
2004
- 2004-09-08 US US10/570,971 patent/US20060234297A1/en not_active Abandoned
- 2004-09-08 WO PCT/JP2004/013396 patent/WO2005026348A1/ja not_active Application Discontinuation
- 2004-09-08 EP EP04773069A patent/EP1669446A4/en not_active Withdrawn
Non-Patent Citations (6)
Also Published As
Publication number | Publication date |
---|---|
US20060234297A1 (en) | 2006-10-19 |
EP1669446A4 (en) | 2008-07-16 |
EP1669446A1 (en) | 2006-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005103288A1 (ja) | スクリーニング方法 | |
US20100112601A1 (en) | Novel monoclonal antibody and use of the same | |
TWI774717B (zh) | 老年性黃斑部變性症治療用肽及其製造方法 | |
US11318158B2 (en) | Pappalysin regulator | |
WO2004069268A1 (ja) | Otx2遺伝子を用いた網膜視細胞の再生と新生 | |
WO2005026348A1 (ja) | スクリーニング方法 | |
WO2007037245A1 (ja) | 血管新生抑制作用を有するポリペプチド | |
WO2019245012A1 (ja) | 網膜色素変性症治療用ペプチド | |
KR100628917B1 (ko) | 세포장해 단백질 및 그 이용 | |
US20050074754A1 (en) | Novel protein and use thereof | |
WO2002066050A1 (fr) | Inhibiteurs de caspase 3 | |
JP2005102691A (ja) | スクリーニング方法 | |
CN103370340A (zh) | 包含dhFas-1结构域和MMP底物的融合肽及其在预防和治疗类风湿性关节炎中的应用 | |
WO2012101125A1 (en) | Specific antibodies against human cxcl4 and uses thereof | |
RU2788083C2 (ru) | Пептид для лечения возрастной макулярной дегенерации | |
WO2001098341A1 (fr) | Nouveau polypeptide et son adn | |
WO2003084998A1 (fr) | Anticorps monoclonal neutralisant la megsine | |
JPH10324698A (ja) | 新規タンパク質およびそのdna | |
JP2004105174A (ja) | 新規気道上皮細胞株およびその用途 | |
WO2007142276A1 (ja) | 分泌型ヘパリン結合上皮細胞増殖因子様増殖因子の測定方法 | |
JP2001299363A (ja) | 新規タンパク質およびそのdna | |
JP2002335964A (ja) | 新規タンパク質およびその用途 | |
WO2007032559A1 (ja) | 新規モノクローナル抗体及びその用途 | |
JP2002233377A (ja) | 新規タンパク質およびそのdna | |
WO2005030805A1 (ja) | 新規タンパク質複合体およびその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004773069 Country of ref document: EP Ref document number: 2006234297 Country of ref document: US Ref document number: 10570971 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004773069 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10570971 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |